The present disclosure relates to novel crystalline forms of a sodium-glucose co-transporter inhibitor drug (Sotagliflozin), processes for preparation and use thereof. The present disclosure also relates to pharmaceutical composition comprises novel crystalline forms of Sotagliflozin and use of novel crystalline forms and pharmaceutical composition of Sotagliflozin for preparing drugs for treating diseases. The crystalline forms provided by the present disclosure have advantages of good stability, relatively low hygroscopicity, suitability for process development and post-treatment, simple processes for preparation, low cost, and has significant value for future drug optimization and development.
